DexCom

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade DexCom 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About DXCM

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. 

CEO
Jacob S. Leach
CEOJacob S. Leach
Employees
10,300
Employees10,300
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1999
Founded1999
Employees
10,300
Employees10,300

DXCM Key Statistics

Market cap
26.28B
Market cap26.28B
Price-Earnings ratio
37.51
Price-Earnings ratio37.51
Dividend yield
Dividend yield
Average volume
3.80M
Average volume3.80M
High today
$69.23
High today$69.23
Low today
$65.60
Low today$65.60
Open price
$68.61
Open price$68.61
Volume
7.87M
Volume7.87M
52 Week high
$93.25
52 Week high$93.25
52 Week low
$54.11
52 Week low$54.11

Stock Snapshot

With a market cap of 26.28B, DexCom(DXCM) trades at $67.34. The stock has a price-to-earnings ratio of 37.51.

As of 2026-01-11, DexCom(DXCM) stock has fluctuated between $65.60 and $69.23. The current price stands at $67.34, placing the stock +2.7% above today's low and -2.7% off the high.

The DexCom(DXCM)'s current trading volume is 7.87M, compared to an average daily volume of 3.8M.

In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.

In the last year, DexCom(DXCM) shares hit a 52-week high of $93.25 and a 52-week low of $54.11.

DXCM News

TipRanks 2d
DexCom price target raised to $86 from $84 at Bernstein

Bernstein raised the firm’s price target on DexCom (DXCM) to $86 from $84 and keeps an Outperform rating on the shares. After a low point in September 2025, U.S...

Simply Wall St 3d
Why Dexcom Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform

Dexcom has appointed long-time leader Jake Leach as President and CEO effective 1 January 2026, while advancing plans to roll out an AI-enabled Stelo app and ex...

Why Dexcom Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
15.2%
Sell
0%

People also own

Based on the portfolios of people who own DXCM. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.